Invesco Ltd. Amylyx Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$2.71 - $19.57 $1,230 - $8,884	454 Added 1.9%	24,349 $69,000
Q4 2023 Feb 12, 2024	SELL	$12.07 - $18.46 $71,695 - $109,652	-5,940 Reduced 19.91%	23,895 $351,000
Q3 2023 Nov 13, 2023	BUY	$18.08 - $23.45 $55,957 - $72,577	3,095 Added 11.57%	29,835 $546,000
Q2 2023 Aug 11, 2023	BUY	$20.98 - $31.42 $79,786 - $119,490	3,803 Added 16.58%	26,740 $576,000
Q1 2023 May 12, 2023	SELL	$27.71 - $40.93 $5.34 Million - $7.88 Million	-192,533 Reduced 89.35%	22,937 $672,000
Q4 2022 Feb 13, 2023	SELL	$29.75 - $39.26 $1.37 Million - $1.81 Million	-46,066 Reduced 17.61%	215,470 $7.96 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $4.49 Million - $8.09 Million	261,536 New	261,536 $7.36 Million

140

44.6M

226K

909K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $180M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

Stay updated on Invesco Ltd. with notifications on news.